West and coworkers (6) reported differences in the sensitivities of MRC-5 monolayers to cytomegalovirus (CMV) among different suppliers (i.e., Whittaker Bioproducts, Bartels, and ViroMed). The authors further suggested that pretreatment of shell vials with the (glucocorticoid) dexamethasone plus dimethyl sulfoxide (DEX-DMSO) and DEX-DMSO plus Ca enhanced CMV recovery and that this effect was most pronounced in shell vials supplied by Whittaker. On the basis of recent studies by this worker and colleagues (4, 5), some important questions in experimental design should be brought to the attention of the readership of the Journal of Clinical Microbiology before the conclusions by the SmithKline investigators are drawn.
West and coworkers (6) reported differences in the sensitivities of MRC-5 monolayers to cytomegalovirus (CMV) among different suppliers (i.e., Whittaker Bioproducts, Bartels, and ViroMed). The authors further suggested that pretreatment of shell vials with the (glucocorticoid) dexamethasone plus dimethyl sulfoxide (DEX-DMSO) and DEX-DMSO plus Ca enhanced CMV recovery and that this effect was most pronounced in shell vials supplied by Whittaker. On the basis of recent studies by this worker and colleagues (4, 5) , some important questions in experimental design should be brought to the attention of the readership of the Journal of Clinical Microbiology before the conclusions by the SmithKline investigators are drawn.
Firstly, and perhaps most importantly, studies by Leonardi and Lipson (4) and Lipson et al. (5) using laboratoryadapted and wild CMV strains as well as freshly collected peripheral blood demonstrated that MRC-5 monolayer sensitivity may be enhanced following a medium enrichment effect. In our studies specifically, monolayer sensitivity was enhanced and CMV isolation was increased in shell vials pretreated with Eagle minimal essential medium supplemented with 10% heat-inactivated fetal bovine serum (EMEM-10% FBS) compared with EMEM-2% FBS. Regarding the West et al. (6) study, I cannot help but question whether refeeding with an enriched culture medium, that is, EMEM-10% FBS (toxic cellular metabolites would be removed from the system by this step as well), might have increased the sensitivity and overall recovery rate of CMV in the untreated shell vials to the levels obtained by using monolayers pretreated with EMEM-2% FBS plus DEX-DMSO or DEX-DMSO-Ca. According to our data, for example, no significant differences were identified in the rates of CMV recovery from blood specimens which were inoculated into shell vials pretreated with either DMSO or EMEM-10% FBS (5) .
A second point arises with the fact that most diagnostic virology laboratories do not recommend that potentially CMV-positive clinical specimens remain in storage (at a refrigeration temperature [i.e., 4°C]) longer than from 24 to 48 h. Ideally, such specimens should be received and processed by the laboratory within hours of collection (1, 5) . The testing of 1-to 2-week-old preselected positive clinical specimens (the authors claim that "the number of [shell] vials available from each supplier was limited"), although extremely convenient for such comparative studies, may not necessarily reflect that which may take place when freshly collected clinical specimens are tested. Although the data of West et al. (6) imply differences in the sensitivities of MRC-5 cultures supplied by different manufacturers, the development of artifacts (possibly due to, e.g., the formation of particulates-precipitates or changes in pH) in the 1 (2, 3) . We saw absolutely no difference in the appearance of CMV inclusions with these fresh specimens and that of CMV inclusions with our older specimens and no evidence of false positives caused by "artifacts" or "particulates-precipitates" with our monoclonal anti-CMV antibodies. Neither have we found any accounts of such false positives in the literature or heard of them from colleagues. What we have seen, rather, is a loss in viability of the virus with storage, resulting in specimens becoming negative. We took advantage of this fact to push our system to the limit and to create a more rigorous test of sensitivity by including a larger percentage of these borderline positives. Another reason for using previously determined positives was the expense of shell vials. We did not wish to waste large numbers of them on negative specimens which would not figure into our data.
Another point worth touching on is the fact that methods of virus recovery may vary considerably with the type of specimen involved. Judging from the titles of Dr. Lipson's papers and abstract (1), two out ot three of these articles deal with CMV in blood specimens. None of our studies have included blood specimens.
Along (2) . We would add that any assessment of optimal GVTs should consider the impact of the timing of test results on patient therapy and clinical outcome. We recently assessed these issues with BACTEC PEDS Plus (PP) medium.
PP medium is used with the BACTEC NR 660 system (Becton Dickinson Diagnostic Instruments, Sparks, Md.) to diagnose bloodstream infection in children. PP medium contains less broth and less sodium polyanetholesulfonate than other BACTEC media and contains resins, and comparative clinical studies have generally shown increased microbial recovery with reduced detection time (1, 3, 5) . When PP medium is used, the manufacturer recommends a GVT of 20 be used to denote positivity for vials contain ing 1 to 2 ml of blood and a lower GVT be used for vials with less blood. Because the volume of blood submitted from children, particularly neonates, may be less than 1 ml (1, 4), we evaluated the benefits of lowering the GVT of the first laboratory run of blood cultures submitted in PP medium on work load, yield of pathogens, and impact on therapy.
From October 1990 through August 1991 all specimens received in PP medium were classified as PR or PN (Peds routine or neonate), the latter if they were from neonates or if there was visibly little blood. Specimens arriving before 6:00 a.m. were sampled twice on day 1; those arriving from 6:00 to 9:30 a.m. were sampled once. All vials were sampled twice on day 2 and once on days 3, 5, and 7. For vials run twice on day 1, the initial GVT was set at 10 for PN specimens and 15 for PR specimens; all subsequent GVTs were set at 20.
During the study, 9,458 bottles were processed; 8,409 (8,037 PR and 372 PN) were sampled twice on day 1. Of these latter bottles, 167 (2%) were positive with an initial GVT of <20; 140 (84%) were false positives. There were 24 true positives from PR specimens (23 staphylococci, including 2 S. aureus, and 1 Neisseria sicca with alpha-hemolytic streptococcus) and 3 true positives from PN specimens (2 coagulasenegative staphylococci and 1 alpha-hemolytic streptococcus). In the four patients with bacteremia due to "usual pathogens" (as defined by McGowan and Metchock [2] ), antibiotic therapy was not affected by earlier results. Only the patients with S. aureus bacteremia, already on appropriate antibiotics, were considered to have true bacteremia.
In our institution, lowering the GVT to <20 on the first day-1 reading for PP bottles resulted mainly in false positives, and only 7.4% of the true positives were usual pathogens. The technical work of processing the false positives totalled 23 h plus the cost of unnecessary subcultures. We concluded that the potential impact of this lowered GVT on patient care was minimal, and we now only use a GVT of 20 with PP medium. We agree that individual laboratory assessment of the GVT The advent of the shell vial culture technique (3) has resulted in a more sensitive method for the recovery of human cytomegalovirus (HCMV) from clinical specimens as well as a considerably shortened detection time for this virus compared with that of standard tube culturing (4) . Studies in our laboratory have shown that this sensitivity can be increased by pretreatment of the cells with medium containing dexamethasone (DEX) and by the addition of DEX plus dimethyl sulfoxide (DMSO) to the centrifugation and incubation steps (8) . Sensitivity can be increased even further by the inclusion of 2 mM calcium in the medium in the latter two steps (9) . MRC-5 cells grown in shell vials from Whittaker Bioproducts were used in those experiments (8, 9) . Similar results were seen by investigators using MRC-5 cells grown in their own laboratory and treated with DEX alone (7) .
In recent investigations with MRC-5 shell vials from other commercial suppliers, no enhancement of HCMV detection was noted with DEX and DMSO (2, 5) . This result prompted us to compare the performance of MRC-5 shell vials from Whittaker, Bartels, and ViroMed with regard to the detection of HCMV in both treated and untreated cell systems.
It has been suggested by one group of investigators that since they recorded enhancement of sensitivity to HCMV AD169 with DEX-DMSO but no enhancement of sensitivity to clinical specimens, the effect might be found only for laboratory-adapted strains of virus (2) . To determine whether this suggestion was true, we tested the AD169 strain in parallel with a wild-type strain of virus obtained from a clinical urine specimen. We inoculated both strains into treated and untreated vials from all three companies and counted the resulting fluorescent foci.
In a previous study, we found that the cell treatments increased the protein content of individual vials, the result of * Corresponding author. a reproductive spurt in the static cultures (9) . Since HCMV replicates best in actively metabolizing cultures, it would be reasonable to assume that the initiation of this reproductive spurt is at least partly responsible for the enhanced viral detection. In this study, we compared changes in protein levels among the three commercial cell lines.
We also tested a number of clinical specimens that had previously tested positive in DEX-DMSO-Ca-treated cells. We compared the three cell lines for sensitivity in virus recovery and also for relative numbers of fluorescent foci per coverslip. during the pretreatment period, since we wished to mimic actual procedures used in the majority of clinical virology laboratories. However, some preliminary experiments in which the medium in the untreated groups was changed to EMEM-2% FBS for the pretreatment period were done (data not shown). No differences were noted in the response of these cells and the cells preincubated in shipping medium. In addition, the Whittaker cells showed progressive enhancement in viral detection with DEX-DMSO and DEX-DMSO-Ca treatments. This enhancement was less pronounced in cells from the other suppliers (Fig. 1) . The results seen in Fig. 1 were duplicated when a specimen-derived wild-type virus strain was treated in the same manner as strain AD169 (Fig. 2) . Responses of cells from the three companies to treatmentinduced changes in total protein content per coverslip were compared. All three cell lines responded to both treatments, yet significant differences among the cell lines were not found (Fig. 3) . Because of limited supplies of vials, cells from only one set of coverslips were counted to determine whether cell numbers increased with treatment (data not shown). This set showed the same pattern of progressive increases as was seen in a previous study (9) . Finally (9) . In published reports of a failure to confirm our findings, investigators used MRC-5 cells from a source other than ours (2, 5) . The possibility that cells from different sources have different sensitivities to HCMV and different responses to cell treatments was therefore investigated. As a result of these studies, cells from Whittaker have been shown to be more sensitive without any treatment and also more responsive to treatment with either DEX-DMSO or DEX-DMSO-Ca. This result was true for a wild-type strain of virus obtained directly from a specimen as well as for culture-adapted strain AD169.
MATERIALS AND METHODS

Cells
Clinical specimens that had previously tested positive showed a certain amount of variation when retested with cells from the three sources. The differences in the number of inclusions were larger in some samples than in others. Of 36 clinical specimens, 6 were recovered only in Whittaker cells.
The factor(s) responsible for our results has not been identified. DEX and calcium are both known to stimulate a reproductive spurt in contact-inhibited, static cultures (9) . Perhaps there are metabolic differences among the cell lines, with the Whittaker cells being more completely stimulated into the growth phase. However, the stimulation of protein accumulation and increases in cell numbers by the treatments occurred with all of the cell lines tested. This result might argue that a growth spurt causes the enhancement of sensitivity by the treatments, but it does not explain differences in the sensitivities of treated cells, nor does it explain the differences in sensitivities among untreated cells.
The genetic differences among the cells from various sources are even less clear. It seems unlikely that a diploid cell line with a finite life span would show significant genetic variations at the passage number involved. It is conceivable that media, sera, or handling or shipping conditions are responsible. Perhaps, because of unidentified differences in treatment, the cells from the three sources have undergone a different number of cell doublings. Further investigations should be carried out to identify characteristics of these cell lines which will increase the sensitivity and accuracy of HCMV detection from clinical samples.
